Media Releases › Next Science View All Next Science News Next Science - FY22 Results and FY23 Outlook 28 Feb 2023 10:03 AM Highlights: Audited full-year product revenue of US$11.3m, reflecting a 40% increase on FY21.Total revenue of US$11.7m increased 31% yoy. Gross margin steady at 78%, with Gross Profit increasing 32% on FY21. Underlying EBITDA loss of US$11.8m compared with US$8.7m in FY21. Cash on hand at December US$5.1m. Post balance-date, increased by A$10m from shareholder approval of Secured Convertible Note to Walker Group Holdings Pty Limited. XPERIENCETM (XP) showed steady month-on-month growth through 2HFY22. Commencement of DME operation in 4QFY22 delivering positive early results. Sydney Australia Tuesday, 28 February 2023: Next Science Limited (ASX: NXS) (Next Science) is pleased to release its audited full year results for the period ended 31 December 2022. For more information, download the attached PDF. Download this document
